

HCC- UK Annual Conference 'Accelerating improvements for patients with HCC' Bridgewater Hall, Manchester

Thursday 27th March 2025 – Basic and Translational Science Day

10:55-11:55 Registration – arrivals, refreshments and networking

<u>Session 1 – Advancements in integrative AI (Chair: Dr Matthew Hoare)</u>

- 11:55-12:00 *Welcome and Introduction* Professor Tom Bird, Consultant Hepatologist, University of Glasgow
- 12:00-12:25 Integrative computation in cancer biology Crispin Miller, CRUK Scotland Institute
- 12:25-12:55 AI in liver disease Professor Jakob Kather, Technical University Dresden
- 12:55-13:10 Multiomic analysis demonstrates hepatocyte SOX9 loss exacerbates fibrosis and HCC development Dr Elliot Jokl, University of Manchester

13:10-14:05 Lunch and poster viewing

<u>Session 2 – Keynote session (Chair: Prof Tom Bird)</u>


- 14:05 14:20 Novel multiomics biomarker signature derived from blood circulating hepatocyte-extracellular vesicles for the early detection of HCC Dr Tomas Dias, Mursla Bio
- 14:20-14:35 The translational repressor, eIF4A2, promotes extracellular matrix deposition to accelerate hepatocellular carcinoma initiation Dr Madeleine Moore, CRUK Scotland Institute
- 14:35 14:50 Fine needle aspirates capture immunotherapy biomarkers and targets compartmentalised within hepatocellular carcinoma tumours Dr Gloryanne Aidoo-Micah, University College London
- 14:50 15:05 Harnessing enclysis to control regulatory T cell frequencies in the liver tumour microenvironment Dr Zania Stamataki, University of Birmingham
- 15:05 15:40 *Genetics of adenoma and HCC progression* Professor Jessica Zucman Rossi, University Paris Descartes

15:40-16:00 Tea and Coffee



Session 3 - Tumour evolution in metabolic liver disease (Chair: Prof Shish Shetty)

- 16:00 16:20 Hepatic cell evolution in premalignant MASLD Professor Ram DasGupta, University of Glasgow
- 16:20 16:45 *Metabolic heterogeneity in HCC: searching for new targets of treatment* Professor Patricia Aspichueta, Universidad del País Vasco, Spain.
- 16:45 17:00 Epigenetic regulation of liver endothelial cells as a novel target to boost immunotherapy efficacy in hepatocellular cancer Mr Saad Rehman



Friday 28th March 2025 - Clinical Day

8:00-9:00 Registration and coffee

9:00-9:05 Welcome and Introduction to the Clinical Day – Dr Richard Hubner, Consultant medical oncologist

Session 4 – Radiotherapy and clinical innovations (Chair: Prof Tim Meyer)

- 9.05 9.35 *New therapies: Proton Beam therapy* Professor Maria Hawkins and Dr Ganesh Radhakrishna
- 9.35 9:50 Identification of novel phosphoproteomic signatures predictive of response to atezolizumab and bevacizumab (AB) in a UK cohort of patients with advanced hepatocellular carcinoma (aHCC) Dr Christina Karampera, King's College Hospital
- 9:50 10:05 Clinical predictors of overall survival after transarterial radioembolisation (TARE) for hepatocellular carcinoma (HCC): a retrospective analysis Dr Saur Hajiev, Cambridge Liver Unit
- 10:05 -10:20 SHiNE-UK: A national evaluation of hepatocellular carcinoma surveillance, routes to diagnosis and treatment utilisation Dr Christopher Mysko, University of Manchester
- 10:20 10:35 A retrospective analysis of hepatocellular carcinoma patients receiving first line atezolizumab/bevacizumab versus lenvatinib at the Royal Free Hospital between 2017 and 2024 Adam Cheung, UCL



10:35-10:50 *Liver Cancer: an update from the British Liver Trust* - Pamela Healy, Chief Executive British Liver Trust

10:50-11:50 Coffee, posters and exhibition

11:00-11:30 Sponsored Symposium - AstraZeneca

Championing patient-centred care in the anti-cancer immunotherapy era of HCC - Prof. Tom Bird; Hepatologist and Dr David Pinato; Medical Oncologist

<u>Session 5 – Early stage disease (Chair: Dr Abid Suddle)</u>

11.50 – 12.15 Live Donor Liver transplantation – Miriam Cortescerisuelo

12.15 – 12.35 Evaluation and optimisation of portal hypertension for patients with HCC Dhiraj Tripathi, Birmingham

12:35-13.10 The role of neoadjuvant immunotherapy in liver transplantation and liver resection for HCC – Dr David Pinato

13:10-14:15 Lunch, posters and exhibition

Session 6 - Decision making in the MDT (Chair: Dr Aileen Marshall)

14:15 – 15:15 HCC MDT – Interactive Cases - Diagnostic difficulties in Hepatocellular carcinoma

Cases

- 1. Dr Abid Suddle Consultant Hepatologist, Kings College, London
- 2. Dr Anna Paterson, Consultant Histopathologist, Cambridge University Hospitals.
- 3. Dr Aileen Marshall & Professor Tim Meyer Royal Free London

MDT panel

Kelly Farrell - Clinical Nurse Specialist, The Christie NHS Foundation Trust, Manchester
Dr Ian Rowe - Associate Professor & Honorary Consultant Hepatologist, University of Leeds, Leeds
Dr Alexa Childs - Postdoctoral clinical research fellow and honorary consultant in oncology, Royal
Free Hospital, London

Dr Anna Paterson, Consultant Histopathologist, Cambridge University Hospitals.

Mr Jack Martin – University of Cambridge

Dr Umberto Pisano - Interventional Radiology & Interventional Oncology Consultant, NHS Greater Glasgow and Clyde

Session- 7 New frontiers in HCC (Chair: Dr Richard Hubner)

15:15-15:45 Systemic therapy combined with locoregional therapy – state of the art -Dr Alexa Childs



15:45-16:15 *Metabolic associated steatotic liver disease and HCC* - Professor Helen Reeves, Newcastle

16:15-16:25 Conclusion/Farewell/Prize giving

BASL PARTNERS





SILVER SPONSORS





EXHIBITION SPONSORS





